References

Cases

Health economic analysis of Rydapt for treatment of AML patients in Belgium
Novartis, a large international pharmaceutical company applied for the Class 1 reimbursement of the new drug, Rydapt, to treat patients with acute myeloid leukaemia who are FLT3 mutation-positive....
Cost Effectiveness and Budget Impact
A large international pharmaceutical company was applying for the reimbursement of a new indication of an existing product.  As the reimbursement request was for an orphan drug, a cost-...
Curando Logo
A major change in the past year was the ‘Curando HOP’ project coached by hict, with the aim of harmonisation and optimisation of all the processes. In line with this project a second project...

Our clients

Abbott Diagnostics
Belgium & UK
Abbvie
Belgium
Adinfo
Belgium
Agfa Healthcare nv
Belgium
Al-Ahli Hospital
Qatar
Amgen
Europe
AstraZeneca
Belgium
AZ Damiaan, Oostende
Belgium
AZ Glorieux
Belgium
AZ Heilige Familie Rumst
Belgium
AZ Jan Portaels
Belgium
AZ Maria Middelares
België
AZ Nikolaas
Belgium
AZ Sint-Augustinus Veurne
Belgium
AZ Sint-Blasius
Belgium
Ezelstraat 69 | B- 8000 Brugge | Belgium | Phone: +32.50.33.33.40 | Fax: +32.50.33.33.39 | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: info@hict.com